Effectiveness of direct-acting antiviral (DAA) agents on hepatitis C virus-related mixed cryoglobulinemia syndrome: One-year follow-up
-
Published:2023-04
Issue:2
Volume:45
Page:139-143
-
ISSN:1110-1164
-
Container-title:The Egyptian Rheumatologist
-
language:en
-
Short-container-title:The Egyptian Rheumatologist
Author:
Fayed Hala L.ORCID,
Abd El Ghany Sohair M.,
Nasser Abeer M.,
El-gendy Naglaa A.
Reference34 articles.
1. Quartuccio L, Bortoluzzi A, Scirè CA, Marangoni A, Del Frate G, Treppo E, et al. Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC). Clin Rheumatol. 2022; ebub ahead of print.
2. Dermatologic extrahepatic manifestations of hepatitis C;Dedania;J ClinTransl Hepatol,2015
3. Efficacy and safety of combined pegylated interferon/ribavirin therapy in the management of rheumatological manifestations of chronic HCV patients;El-Garf;Egyptian Rheumatologist,2016
4. The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents;Roccatello;Oncotarget,2017
5. Zignego AL and Ferri C:Cryoglobulinaemia;Roccatello;Nat Rev Dis Primers,2018
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献